@article{LvZhangZhuetal.2015,
  author    = {Lv, Xiaoqun and Zhang, Lingyun and Zhu, Yanyan and Said, Harun M. and Shi, Jimin and Xu, Guoxiong},
  title     = {Regulative effect of Nampt on tumor progression and cell viability in human colorectal cancer},
  series = {Journal of Cancer},
  volume    = {6},
  journal   = {Journal of Cancer},
  number    = {9},
  doi       = {10.7150/jca.12341},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-144516},
  pages     = {849-858},
  year      = {2015},
  abstract  = {Colorectal cancer (CRC) is the third most common cancer disease. Here we examined Nampt expression in patients with CRC and the effect of Nampt on cell viability in CRC cells. Nampt protein was overexpressed in colorectal adenoma as well as colorectal carcinoma. The immunoreactive staining of Nampt was negative in the adjacent normal colorectal tissue, weak in colorectal adenoma, and strong in colorectal carcinoma, which may represent tumor progression. Further evaluation of clinical data showed that Nampt expression was not correlated with the clinicopathological characteristics of CRC. Additionally, our in vitro studies demonstrated that Nampt promotes CRC cell viability, whereas the Nampt inhibitor FK866 suppressed CRC cell viability, which was in concordance with the previous studies in other cancer cells. Treatment with Nampt-siRNA reduced the Nampt protein expression resulting in the inhibition of the cell viability of HCT116 and Caco2. Thus, the involvement of Nampt in cell growth indicates that Nampt may play an important role in colorectal tumorigenesis. As a consequence, our results suggest that Nampt may be considered as a progression marker of colorectal tumor and a potentially therapeutic target for the treatment of CRC.},
  language  = {en}
}
@article{WesterKellerSchotteliusetal.2015,
  author    = {Wester, Hans J{\"u}rgen and Keller, Ulrich and Schottelius, Margret and Beer, Ambros and Philipp-Abbrederis, Kathrin and Hoffmann, Frauke and Šimeček, Jakub and Gerngross, Carlos and Lassmann, Michael and Herrmann, Ken and Pellegata, Natalia and Rudelius, Martina and Kessler, Horst and Schwaiger, Markus},
  title     = {Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging},
  series = {Theranostics},
  volume    = {5},
  journal   = {Theranostics},
  number    = {6},
  doi       = {10.7150/thno.11251},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-144537},
  pages     = {618-630},
  year      = {2015},
  abstract  = {Chemokine ligand-receptor interactions play a pivotal role in cell attraction and cellular trafficking, both in normal tissue homeostasis and in disease. In cancer, chemokine receptor-4 (CXCR4) expression is an adverse prognostic factor. Early clinical studies suggest that targeting CXCR4 with suitable high-affinity antagonists might be a novel means for therapy. In addition to the preclinical evaluation of [\(^{68}\)Ga]Pentixafor in mice bearing human lymphoma xenografts as an exemplary CXCR4-expressing tumor entity, we report on the first clinical applications of [\(^{68}\)Ga]Pentixafor-Positron Emission Tomography as a powerful method for CXCR4 imaging in cancer patients. [\(^{68}\)Ga]Pentixafor binds with high affinity and selectivity to human CXCR4 and exhibits a favorable dosimetry. [\(^{68}\)Ga]Pentixafor-PET provides images with excellent specificity and contrast. This non-invasive imaging technology for quantitative assessment of CXCR4 expression allows to further elucidate the role of CXCR4/CXCL12 ligand interaction in the pathogenesis and treatment of cancer, cardiovascular diseases and autoimmune and inflammatory disorders.},
  language  = {en}
}
@article{SchwitterWackerWilkeetal.2012,
  author    = {Schwitter, Juerg and Wacker, Christian M. and Wilke, Norbert and Al-Saadi, Nidal and Sauer, Ekkehart and Huettle, Kalman and Sch{\"o}nberg, Stefan O. and Debl, Kurt and Strohm, Oliver and Ahlstrom, Hakan and Dill, Thorsten and Hoebel, Nadja and Simor, Tamas},
  title     = {Superior diagnostic performance of perfusion-cardiovascular magnetic resonance versus SPECT to detect coronary artery disease: The secondary endpoints of the multicenter multivendor MR-IMPACT II (Magnetic Resonance Imaging for Myocardial Perfusion Assessment in Coronary Artery Disease Trial)},
  series = {Journal of Cardiovascular Magnetic Resonance},
  volume    = {14},
  journal   = {Journal of Cardiovascular Magnetic Resonance},
  number    = {61},
  organization    = {MR-IMPACT investigators},
  doi       = {10.1186/1532-429X-14-61},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-134256},
  year      = {2012},
  abstract  = {Background: Perfusion-cardiovascular magnetic resonance (CMR) is generally accepted as an alternative to SPECT to assess myocardial ischemia non-invasively. However its performance vs gated-SPECT and in sub-populations is not fully established. The goal was to compare in a multicenter setting the diagnostic performance of perfusion-CMR and gated-SPECT for the detection of CAD in various populations using conventional x-ray coronary angiography (CXA) as the standard of reference. Methods: In 33 centers (in US and Europe) 533 patients, eligible for CXA or SPECT, were enrolled in this multivendor trial. SPECT and CXA were performed within 4 weeks before or after CMR in all patients. Prevalence of CAD in the sample was 49\% and 515 patients received MR contrast medium. Drop-out rates for CMR and SPECT were 5.6\% and 3.7\%, respectively (ns). The study was powered for the primary endpoint of non-inferiority of CMR vs SPECT for both, sensitivity and specificity for the detection of CAD (using a single-threshold reading), the results for the primary endpoint were reported elsewhere. In this article secondary endpoints are presented, i.e. the diagnostic performance of CMR versus SPECT in subpopulations such as multi-vessel disease (MVD), in men, in women, and in patients without prior myocardial infarction (MI). For diagnostic performance assessment the area under the receiver-operator-characteristics-curve (AUC) was calculated. Readers were blinded versus clinical data, CXA, and imaging results. Results: The diagnostic performance (= area under ROC = AUC) of CMR was superior to SPECT (p = 0.0004, n = 425) and to gated-SPECT (p = 0.018, n = 253). CMR performed better than SPECT in MVD (p = 0.003 vs all SPECT, p = 0.04 vs gated-SPECT), in men (p = 0.004, n = 313) and in women (p = 0.03, n = 112) as well as in the non-infarct patients (p = 0.005, n = 186 in 1-3 vessel disease and p = 0.015, n = 140 in MVD). Conclusion: In this large multicenter, multivendor study the diagnostic performance of perfusion-CMR to detect CAD was superior to perfusion SPECT in the entire population and in sub-groups. Perfusion-CMR can be recommended as an alternative for SPECT imaging.},
  language  = {en}
}
@phdthesis{Kung2004,
  author    = {Kung, Margret},
  title     = {Diagnostische und prognostische Wertigkeit der kontrastmittelverst{\"a}rkten Dobutamin-Stressechokardiographie bei herztransplantierten Patienten},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-10133},
  school      = {Universit{\"a}t W{\"u}rzburg},
  year      = {2004},
  abstract  = {F{\"u}r Patienten im terminalen Stadium der Herzinsuffizienz bleibt h{\"a}ufig als letzte Alternative die orthotope Herztransplantation. Weltweit wurden bis heute 63.000 Herztransplantationen durchgef{\"u}hrt. Postoperativ sind lebenslang engmaschige Kontrolluntersuchungen notwendig, um typische Komplikationen wie Transplantatvaskulopathie, akute Transplantatabstoßung, Myokardfibrose und andere Begleiterkrankungen fr{\"u}hzeitig diagnostizieren und therapieren zu k{\"o}nnen. Trotz der Notwendigkeit regelm{\"a}ßiger {\"U}berwachung bedeutet die Herztransplantation f{\"u}r viele Patienten eine deutliche Verbesserung ihrer Lebensqualit{\"a}t. Die Komponenten der Nachsorge von herztransplantierten Patienten sind komplex, so dass diese vorwiegend an spezialisierten Einrichtungen erfolgt.7 Aufgrund der verbesserten immunsuppressiven Therapie und der dadurch bedingten l{\"a}ngeren {\"U}berlebenszeiten nach Herztransplantation gewinnt die Transplantatvaskulopathie in der Langzeitprognose immer mehr an Bedeutung. Die Echokardiographie in Ruhe und unter Belastung ist die wichtigste nicht-invasive Methode, um mit der Transplantatvaskulopathie einhergehende Wandbewegungsst{\"o}rungen rasch und kosteng{\"u}nstig zu diagnostizieren. Voraussetzung f{\"u}r eine aussagekr{\"a}ftige Beurteilung von Wandbewegungsst{\"o}rungen ist die gute Abgrenzbarkeit von Cavum und Endokard. Die Verwendung von lungeng{\"a}ngigen Kontrastmitteln erlaubt eine bessere ventrikul{\"a}re Kontrastierung und Endokarddelineation. Durch vergleichende Untersuchungen der eigenen Arbeitsgruppe zwischen nativen Dobutamin- Stressechokardiographien (DSE) mit intravaskul{\"a}rem Ultraschall und der Koronarangiographie wurde die DSE als sensitive Methode zur Detektion der Transplantatvaskulopathie etabliert. Es ist jedoch ungekl{\"a}rt, ob eine bessere Kontrastierung des Cavums nach Kontrastmittelapplikation eine pr{\"a}zisere Detektion von Wandbewegungsst{\"o}rungen bei herztransplantierten Patienten und damit eine zuverl{\"a}ssigere Aussage zur Langzeitprognose erlaubt. Akosah et al. konnten bereits zeigen, dass der nativen Dobutamin-Stressechokardiographie eine prognostische Aussagekraft bez{\"u}glich kardialer Ereignisse zukommt. Zur prognostischen Aussagekraftder kontrastmittelverst{\"a}rkten Dobutamin-Stressechokardiographie liegen bislang keine ver{\"o}ffentlichten Daten vor. Ebenso ist unklar, ob und welche im klinischen Alltag routinem{\"a}ßig erhobenen Patientencharakteristika und Verlaufsparameter zur Prognoseabsch{\"a}tzung beitragen. Die vorliegende Arbeit untersucht an einem konsekutiv rekrutierten Kollektiv herztransplantierter Patienten die diagnostische und prognostische Wertigkeit der kontrastmittelverst{\"a}rkten Dobutamin-Stressechokardiographie.},
  language  = {de}
}